Skip to search formSkip to main contentSkip to account menu

OSI 906

Known as: OSI-906, IGF-1R inhibitor OSI-906, OSI906 
National Institutes of Health

Related topics

Related topics

1 relation
linsitinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors.
2559 Background: OSI-906 is a potent small molecule inhibitor of IGF-1R, a receptor tyrosine kinase activated by insulin like… 
2015
2015
Retraction Note to: Lactoferrin promote primary rat osteoblast proliferation and differentiation via up-regulation of insulin-like growth factor-1 expression
2014
2014
OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells.
Ovarian cancer-associated antigen 66 (OVA66), also known as CML66 (GenBank Accession No. AF283301), was first identified in an… 
Review
2014
Review
2014
International randomized, double-blind, placebo-controlled, phase 3 study of linsitinib (OSI-906, L) in patients (pts) with locally advanced or metastatic adrenocortical carcinoma (ACC).
4507 Background: ACC is an uncommon but frequently fatal cancer. For pts with metastatic or recurrent nonoperable ACC, there are… 
2014
2014
RETRACTED ARTICLE: Lactoferrin promote primary rat osteoblast proliferation and differentiation via up-regulation of insulin-like growth factor-1 expression
The aim of this study was to explore the effect of lactoferrin (LF) in primary fetal rat osteoblasts proliferation and… 
Highly Cited
2013
Highly Cited
2013
Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
Purpose: Results from clinical trials involving resistance to molecularly targeted therapies have revealed the importance of… 
2011
2011
A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced…
3099 Background: OSI-906 is an oral inhibitor of IGF-1R and IR. Increased IGF-1R and IR activity is observed in human cancers and… 
2010
2010
Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid…
3098^ Background: OSI-906 is an oral inhibitor of IGF-1R and IR tyrosine kinases. IGF-1R:EGFR cross-talk contributes to… 
2010
2010
Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with…
2531 Background: OSI-906 is a potent inhibitor of IGF-1R and IR tyrosine kinase activity. Increased IGF-1R activity is observed… 
2007
2007
In vivo evaluation of OSI-906, a novel small molecule kinase inhibitor of the insulin-like growth factor-1 receptor (IGF-1R)
B244 The insulin-like growth factor-1 receptor (IGF-1R) has emerged as a potentially viable target for the development of novel… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)